All Posts

We are proud to announce that Premier Clinical Research, Inc has played a vital role in the development of a groundbreaking treatment for schizophrenia. The most widely used atypical antipsychotic is now available as a once-monthly injection, following its recent approval by the US Food and Drug Administration (FDA).

We at Premier Clinical Research, Inc are proud to announce yet another a significant achievement: the FDA has cleared Click Therapeutic's Motivista (CT-155), the first treatment specifically for the negative symptoms of schizophrenia. This accomplishment is a testament to the hard work of nearly 90 investigative sites, including ours. For too long, treatments have focused on positive symptoms of schizophrenia, leaving negative symptoms like low motivation and social withdrawa

Premier Clinical Research Institute Celebrates FDA Approval of XOCOVA®, the first and only oral medication approved in the United States to help prevent COVID-19 following exposure.

PCRI leads community support effort for De Hostos Senior Center, and the launch of #OIDForSeniors

Premier Clinical Research Institute team participates in NAMI Walks Miami to spread awareness about mental health research.

The first Non-Antipsychotic Drug to Treat Agitation in Dementia, by Axsome Therapeutics, has been approved by the FDA, and we are so proud to have been a part of contributing to this groundbreaking approval. Premier Clinical Research Institute was one of the contributing research sites that provided valuable data to the clinical trials that eventually led to the FDA's approval of the medication, Auvelity for this condition. Auvelity was already FDA-approved as an oral antidep